
How do dose reductions affect overall survival with KISQALI?
Across the 3 trials, overall survival (OS) was studied in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who received one or more dose reductions of KISQALI® (ribociclib). Post hoc analyses of data from the 3 phase III MONALEESA clinical trials assessed OS in patients treated with KISQALI, in combination with an aromatase inhibitor (AI) or fulvestrant, who required dose reduction. Efficacy in the placebo comparator arms was not assessed. Review the data below to learn about KISQALI efficacy data in patients requiring dose reductions.1-5
DOSE REDUCTION DATA
Lowering the dose of KISQALI can help address side effects and, in clinical studies, did not impact efficacy1,3
In the post hoc analyses of data from the 3 MONALEESA trials:
- Time-varying Cox regression analysis of OS by dose reduction
- Results are based on a post hoc analysis; efficacy in the placebo comparator arms was not assessed and should be interpreted with caution
MONALEESA-2: KISQALI + AI in postmenopausal patients who received ≥1 dose reduction

In MONALEESA-2, managing adverse reactions with dose reductions helped patients stay on therapy an average of 6.5 months longer than those without dose reductions.2
AI, aromatase inhibitor; HR, hazard ratio; mOS, median overall survival; OS, overall survival.
MONALEESA-3: KISQALI + fulvestrant in postmenopausal patients who received ≥1 dose reduction
MONALEESA-7: KISQALI + NSAI + goserelin in premenopausal patients who received ≥1 dose reduction
NR, not reached; NSAI, nonsteroidal aromatase inhibitor.
MONALEESA-2 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + letrozole (n=334) vs placebo + letrozole (n=334) in postmenopausal patients with HR+/HER2- mBC who received no prior therapy for advanced disease. OS was a secondary end point; PFS was the primary end point. At a median follow-up of 80 months, mOS was 63.9 months with KISQALI + letrozole (95% CI: 52.4-71.0) vs 51.4 months with placebo + letrozole (95% CI: 47.2-59.7); HR=0.765 (95% CI: 0.628-0.932); P=0.004.6,7
MONALEESA-3 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + fulvestrant (n=484) vs placebo + fulvestrant (n=242) in postmenopausal patients with HR+/HER2- mBC who received no or only 1 line of prior ET for advanced disease. OS was a secondary end point; PFS was the primary end point. Statistical significance was established for the ITT population in the prespecified OS analysis at a median follow-up of 39 months: mOS was not reached with KISQALI + fulvestrant (95% CI: 42.5-NR) vs 40 months with placebo + fulvestrant (95% CI: 37.0-NR); HR=0.724 (95% CI: 0.568-0.924); P=0.00455. In exploratory analyses of the 1L subgroup of patients receiving KISQALI + fulvestrant (n=237) or placebo + fulvestrant (n=128): At a median follow-up of 39 months, mOS was not reached with KISQALI + fulvestrant vs 45.1 months with placebo + fulvestrant; HR=0.70 (95% CI: 0.48-1.02); at a median follow-up of 71 months, mOS was 67.6 months with KISQALI + fulvestrant (95% CI: 59.6-NR) vs 51.8 months with placebo + fulvestrant (95% CI: 40.4-61.2); HR=0.673 (95% CI: 0.504-0.899). Results from the exploratory analyses were not prespecified and were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.6,8-10
MONALEESA-7 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + ET (NSAI or tamoxifen) + goserelin (n=335) vs placebo + ET (NSAI or tamoxifen) + goserelin (n=337) (ITT) in premenopausal patients with HR+/HER2- mBC who received no prior ET for advanced disease. KISQALI is not indicated for concomitant use with tamoxifen. Efficacy results are from a prespecified subgroup analysis of 495 patients who received KISQALI (n=248) or placebo (n=247) with an NSAI + goserelin. OS was a secondary end point; PFS was the primary end point. In the prespecified OS analysis at a median follow-up of 35 months, mOS was not reached with KISQALI + NSAI + goserelin (95% CI: NR-NR) vs 40.7 months with placebo + NSAI + goserelin (95% CI: 37.4-NR); HR=0.699 (95% CI: 0.501-0.976). Statistical significance was established for overall survival in the ITT population; HR=0.71 (95% CI: 0.54-0.95); P=0.00973. At a median follow-up of 54 months (exploratory analysis), mOS was 58.7 months with KISQALI + NSAI + goserelin (95% CI: 48.5-NR) vs 47.7 months with placebo + NSAI + goserelin (95% CI: 41.2-55.4); HR=0.798 (95% CI: 0.615-1.035). Results from the 54-month analysis were not prespecified and were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.6,11-14
1L, first line; ET, endocrine therapy; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; ITT, intent to treat; mBC, metastatic breast cancer; PFS, progression-free survival.
PEER PERSPECTIVE
Nick McAndrew, MD, shares his perspective on KISQALI efficacy data for patients who required dose reductions in HR+/HER2- mBC
What data does Dr McAndrew rely on when choosing KISQALI for his patients with HR+/HER2- mBC? Watch to get his insights on the dose reduction data for KISQALI.
Dr McAndrew has been compensated for his time by Novartis Pharmaceuticals Corporation.



